Publications :: OPKO Health, Inc. (OPK)

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Read the news release

Visit BioReference Health

OPKO Biologics

Jun 17, 2026

Production and Characterization of OPK8801001, a Novel Long-Acting hGH Receptor Antagonist for the Treatment of Acromegaly

OXFORD Academic

Jun 10, 2026

Extended-Release Calcifediol Identifies a Therapeutic Vitamin D Range in Chronic Kidney Disease stage 3-4

Journal of Nephrology

Jun 2, 2026

New insights into the management of secondary hyperparathyroidism in non-dialysis dependent chronic kidney disease: extended release calcifediol

ScienceDirect

Feb 25, 2026

Effect of race, gender and age on intrinsic diurnal variation of serum calcifediol: Insights into vitamin D toxicity

PubMed

Aug 26, 2025

Managing Dysregulated Vitamin D Metabolism in CKD: Time to Update Conventional Wisdom?

Karger

Jun 28, 2025

Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial

PubMed

May 7, 2025

High-dose extended-release calcifediol successfully treated advanced secondary hyperparathyroidism in an end-stage kidney disease patient: a case report

Karger

Feb 21, 2025

Adjunctive active vitamin D (AVD) decreases kidney function during treatment of secondary hyperparathyroidism (SHPT) with extended-release calcifediol (ERC) in non-dialysis chronic kidney disease (ND-CKD)

Karger

Jan 22, 2025

Does Correction of Secondary Hyperparathyroidism with Extended-Release Calcifediol Provide Renoprotection?

Karger

Jan 22, 2025

Sustained Reduction of Elevated Intact Parathyroid Hormone Concentrations with Extended-Release Calcifediol Slows Chronic Kidney Disease Progression in Secondary Hyperparathyroidism Patients

Select a page